Back to search results

Study of Daraxonrasib for Resected Pancreatic Cancer

This study is looking at a drug called daraxonrasib for people who have had surgery to remove pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC). The goal is to see if daraxonrasib, given as oral tablets, is safe and works better than just watching and waiting after standard chemotherapy. This drug is a targeted therapy. You might be able to join if you are at least 18 years old, have a good performance status (meaning you can do most daily activities), and had successful surgery for your PDAC with no signs of the cancer returning or spreading. The main way they will measure success is by looking at how long people live without their cancer coming back (Disease-Free Survival) for up to about 5 years. The current status of this study is unclear, and it plans to enroll 500 people.

Study design
This is a global, randomized, open-label, Phase 3 study. It will compare daraxonrasib to standard observation in patients who have completed chemotherapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for Disease-Free Survival for up to approximately 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07252232

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
PHASE3Ages 18+InterventionalTreatment
Revolution Medicines, Inc.
~500 participants
Updated 2026-09-15 on ClinicalTrials.gov
What's tested:daraxonrasib

At a glance

Recruiting sites
73 of 74 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease-Free Survival (DFS) per Investigator
Measured over Up to approximately 5 years

Conditions

Pancreatic Cancer
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Resected Pancreatic Adenocarcinoma

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07252232

Where you'd take part

This study runs at 74 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Asan Medical Center

    Seoul, South Koreastudy coordinator listed

    Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakotastudy coordinator listed

    Recruiting

  • Cancer Institute Hospital of JFCR

    Tokyo, Japanstudy coordinator listed

    Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spainstudy coordinator listed

    Recruiting

  • Columbia University Medical Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Community Health Network

    Indianapolis, Indianastudy coordinator listed

    Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevadastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Revolution Medicines Study Director
[email protected]
1-844-2-REVMED
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.
Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.
Must have completed most recent treatment within the past 12 weeks.
Adequate organ function (bone marrow, liver, kidney, coagulation).
Documented RAS mutation status.
Able to take oral medications.

Exclusion

Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
Any conditions that may affect the ability to take or absorb study drug.
Major surgery within 28 days prior to randomization.
Patient is unable or unwilling to comply with protocol-required study visits or procedures.

What this trial measures

  • Disease-Free Survival (DFS) per InvestigatorUp to approximately 5 years

    DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.